Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

• Disease Name: Dilated Cardiomyopathy 1W
• MONDO ID: (if available)
• Category: Mendelian

Research Objectives

Please provide a comprehensive research report on Dilated Cardiomyopathy 1W covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

• What is the disease? Provide a concise overview.
• What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
• What are the common synonyms and alternative names?
• Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

• Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
• Risk Factors:

  Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

• Genetic risk factors (causal variants, susceptibility loci, modifier genes)
• Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
• Protective Factors:

  Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

• Genetic protective factors (protective variants, modifier alleles)
• Environmental protective factors (diet, lifestyle, exposures that reduce risk)
• Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

  Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

• Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

  Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

• Pathogenic Variants:
• Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
• Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
• Variant type/class (missense, frameshift, nonsense, splice-site, structural)
• Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
• Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
• Functional consequences (loss of function, gain of function, dominant negative)
• Modifier Genes: Genes that modify disease severity or expression
• Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

  Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

• Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

  Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

• Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

  Search first: CDC databases, WHO, PubMed, NHANES

• Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

  Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

Present this section as an ordered causal chain first, then the detail below. Open with a numbered sequence of mechanistic steps running from the initiating lesion (mutation, exposure, infection) to the clinical manifestation, one step per line, each naming what it causes next. State the causal verb explicitly ("leads to", "results in") and say where a step is inferred rather than demonstrated. Where the mechanism branches, show the branch. The categories below are a checklist of what to cover within those steps, not the organizing structure — a step may draw on several of them, and a category may contribute to several steps.

• Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

  Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

• Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

  Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

• Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

  Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

• Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

  Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

• Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

  Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

• Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

  Search first: PubMed, Gene Ontology, Reactome

• Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

  Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

• Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Molecular Profiling (if available):
• Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
• Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
• Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
• Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
• Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
• Advanced Technologies (if applicable):
• Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
• Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
• Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
• Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

• Organ Level:
• Primary organs directly affected
• Secondary organ involvement (complications, secondary effects)
• Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

  Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

• Tissue and Cell Level:
• Specific tissue types affected (epithelial, connective, muscle, nervous)
• Specific cell populations targeted (with Cell Ontology terms)

  Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

• Subcellular Level:
• Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

  Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

• Localization:
• Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
• Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

• Onset:
• Typical age of onset (congenital, pediatric, adult, geriatric)
• Onset pattern (acute, subacute, chronic, insidious)

  Search first: OMIM, Orphanet, HPO, PubMed

• Progression:
• Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
• Progression rate (rapid, slow, variable)
• Disease course pattern (episodic, relapsing-remitting, progressive, stable)
• Disease duration (self-limited, chronic lifelong)

  Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

• Patterns:
• Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
• Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

• Epidemiology:
• Prevalence (cases per 100,000 at given time)
• Incidence (new cases per 100,000 per year)

  Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

• For Genetic Etiology:
• Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
• Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
• Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
• Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
• Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
• Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
• Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
• Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
• Population Demographics:
• Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
• Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
• Geographic distribution of specific variants
• Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
• Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

• Clinical Tests:
• Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
• Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
• Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
• Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
• Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
• Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
• Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
• Genetic Testing:

  Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

• Overview of recommended genetic testing approach
• Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
• Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
• Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
• Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
• Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
• Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
• FISH > Search first: ClinVar, cytogenetics databases, PubMed
• Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
• Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
• Omics-Based Diagnostics (if applicable):
• RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
• Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
• Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
• Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
• Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
• Clinical Criteria:
• Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
• Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
• Screening:
• Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

• Survival and Mortality:
• Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
• Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
• Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
• Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
• Morbidity and Function:
• Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
• Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
• Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
• Disease Course:
• Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
• Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
• Prediction:
• Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
• Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

• Pharmacotherapy:
• Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
• Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
• Advanced Therapeutics:
• Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
• Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
• RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
• Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
• Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
• Surgical and Interventional:
• Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
• Supportive and Rehabilitative:
• Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
• Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
• Experimental:
• Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
• Treatment Outcomes:
• Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
• Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
• Treatment Strategy:
• Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
• Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
• Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

13. Prevention

• Prevention Levels:
• Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
• Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
• Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
• Immunization: Vaccine strategies (if applicable)

  Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

• Screening and Early Detection:
• Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
• Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
• Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
• Behavioral Interventions: Lifestyle modifications to reduce risk

  Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

• Counseling: Genetic counseling (risk assessment, family planning guidance)

  Search first: NSGC resources, ACMG guidelines, GeneReviews

• Public Health:
• Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
• Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
• Prophylaxis: Preventive medications or procedures

  Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

• Taxonomy: Species affected (with NCBI Taxon identifiers)

  Search first: NCBI Taxonomy

• Breed: Specific breeds affected (with VBO identifiers if applicable)

  Search first: VBO (Vertebrate Breed Ontology)

• Gene: Orthologous genes in other species (with NCBI Gene IDs)

  Search first: NCBI Gene

• Natural Disease:
• Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
• Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
• Comparative Biology:
• Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
• Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
• Transmission (if applicable):
• Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
• Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

• Model Types:
• Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
• Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
• Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
• Genetic Models:
• Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
• Model Characteristics:
• Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
• Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
• Applications:
• Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
• Resources:
• Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

• Cite primary literature (PMID preferred) for all mechanistic and clinical claims
• Prioritize recent reviews and landmark papers
• Include direct quotes from abstracts where possible to support key statements
• Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (NCIT terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Dilated Cardiomyopathy 1W (VCL-associated DCM): comprehensive disease-characteristics report

Executive summary and evidence caveat

Dilated cardiomyopathy 1W (DCM1W) is the historical OMIM-style designation for dilated cardiomyopathy associated with heterozygous variation in VCL, encoding vinculin and its muscle-specific splice isoform metavinculin. The defining phenotype is left-ventricular or biventricular dilation with systolic dysfunction, after excluding coronary disease and abnormal loading conditions sufficient to explain the phenotype. Contemporary evidence requires an important qualification: some metavinculin missense/in-frame variants have functional evidence consistent with disease causation, whereas heterozygous VCL predicted loss-of-function (pLOF) variants appear more often to confer reduced-penetrance susceptibility or a modifier effect than fully penetrant monogenic disease. Thus, “Mendelian DCM1W” should not be interpreted as implying that every heterozygous VCL variant is causal. (hawley2020anassessmentof pages 12-15, hawley2020anassessmentof pages 8-12, olson2002metavinculinmutationsalter pages 1-2)

The strongest recent subtype-specific clinical study is a 2023 series of six infants: median age at diagnosis was 2 months, median LVEF 24%, and five of six recovered normal ventricular function, although one required transplantation. This suggests a potentially recoverable infantile phenotype, but the sample is far too small to provide population-level prognosis. (zahavich2023heartfailurewith pages 1-2)

The following compact table is suitable for a knowledge-base record; the narrative thereafter expands and qualifies its contents.

Table: Compact evidence-based summary of VCL-associated dilated cardiomyopathy, including disease identity, variants, penetrance, phenotype, mechanism, diagnosis, management, models, ontology suggestions, and key uncertainties.

1. Disease information

Definition

DCM is a myocardial disorder with ventricular dilation and impaired systolic function not adequately explained by coronary artery disease, hypertension, valvular disease, or congenital heart disease. One quantitative formulation requires LV end-diastolic dimension above 117% of the age- and sex-predicted value, or LV end-diastolic volume ≥2 SD above normal, together with LVEF <45% and/or fractional shortening <25%. Definitions vary across cohorts; a contemporary registry used LVEF <50% after exclusion of significant coronary disease and abnormal loading. (sammani2021diagnosisandrisk pages 2-4, grasso2024thenew2023 pages 1-2, merlo2020contemporarysurvivaltrends pages 1-4)

Identifiers and synonyms

• Preferred name: Dilated cardiomyopathy 1W.
• Synonyms: DCM1W; VCL-related dilated cardiomyopathy; vinculin-associated DCM; metavinculin-associated DCM; familial dilated cardiomyopathy due to VCL.
• OMIM phenotype: 611407, commonly indexed as DCM1W. VCL gene OMIM: 193065. These identifiers should be checked against the current OMIM release before production ingestion.
• MONDO: no subtype-specific MONDO identifier was verified in the retrieved evidence. Use MONDO:0005021, dilated cardiomyopathy, or MONDO:0016333, familial dilated cardiomyopathy, qualified by VCL, rather than inventing a subtype identifier. Open Targets links VCL to both records. (OpenTargets Search: dilated cardiomyopathy-VCL)
• Orphanet: the broader familial isolated DCM concept is commonly represented by ORPHA:154; this is not VCL-specific.
• ICD-10-CM: I42.0, dilated cardiomyopathy. ICD coding does not resolve DCM1W.
• ICD-11: use the dilated-cardiomyopathy entity under cardiomyopathies; no VCL-specific code was identified.
• MeSH: Dilated Cardiomyopathy; no gene-specific MeSH descriptor.
• Suggested HPO anchor: HP:0001644, Dilated cardiomyopathy.

Data provenance

The disease description is an aggregated disease-level synthesis, not an individual EHR record. Evidence includes human case reports and pedigrees, a cohort assembled from >18,000 diagnostic/research referrals, a six-infant registry series with whole-genome sequencing, population controls, biochemical assays, and animal models. The 2023 real-world implementation statistic below derives from de-identified EHR/claims data rather than DCM1W-specific patients. (hawley2020anassessmentof pages 4-8, zahavich2023heartfailurewith pages 1-2, longoni2023realworldutilizationof pages 1-2)

2. Etiology

Causal and susceptibility factors

The implicated gene is VCL. Vinculin is a mechanosensitive adaptor coupling F-actin to cadherin-associated cell–cell adhesions and integrin-associated cell–matrix adhesions. Metavinculin is generated by muscle-specific alternative splicing and contains an additional 68 amino acids. Both isoforms occur at cardiomyocyte intercalated discs and costameres, major sites of contractile-force transmission. (zemljicharpf2007cardiacmyocytespecificexcisionof pages 1-2, olson2002metavinculinmutationsalter pages 1-2, li2024vinculiny822phosphorylation pages 1-3)

The foundational human study screened 350 unrelated DCM patients and found p.Arg975Trp and p.Leu954del in the metavinculin-specific region. Both affected conserved residues, were absent in 500 controls, and significantly altered actin-filament cross-linking in vitro. Its conclusion stated: “Disruption of force transmission at the thin filament-intercalated disc interface is the likely mechanism.” PMID 11815424; published 29 January 2002; DOI/URL: https://doi.org/10.1161/hc0402.102930. (olson2002metavinculinmutationsalter pages 1-2)

Modern pLOF evidence is statistically strong but penetrance is low. In 18,135 cardiomyopathy-test referrals, 30 heterozygous probands carried 26 unique pLOF variants: 12 nonsense, seven frameshift, six canonical splice variants, and one multi-exon duplication. Rare VCL pLOF variants were enriched in DCM, with OR 9.01 (95% CI 4.93–16.45), or 11.33 (5.80–22.15) under stricter filtering. Published June 2020; DOI/URL: https://doi.org/10.1002/humu.24061. (hawley2020anassessmentof pages 4-8, hawley2020anassessmentof pages 18-20, hawley2020anassessmentof pages 8-12)

Genetic risk and modifiers

Family data do not show uniformly convincing autosomal-dominant segregation. Unaffected heterozygotes and co-occurring variants support incomplete penetrance and possible oligogenic inheritance. Candidate co-contributors reported in VCL-positive cases include MYH7, DSP, TPM1, LAMA4, SCN5A, and MYBPC3. In one pedigree, VCL c.2444A>G (p.Lys815Arg) co-occurred with MYBPC3 p.Arg177Cys in more severely affected relatives, but modification was suggested rather than proved. (hawley2020anassessmentof pages 12-15, hawley2020anassessmentof pages 8-12, wells2011familialdilatedcardiomyopathy pages 3-4)

Environmental and gene–environment risk

No exposure is established specifically for DCM1W. Plausible “second hits” derive from DCM generally: viral myocarditis/inflammation, alcohol, anthracyclines and other cardiotoxic drugs, radiation, sustained tachyarrhythmia, hypertension, pregnancy, endocrine/metabolic disease, and heavy-metal exposure. VCL pLOF has been proposed to sensitize myocardium to such stress, but direct human VCL-by-exposure interaction estimates are unavailable. Mouse Vcl haploinsufficiency is comparatively mild at baseline but markedly worsens after pressure overload, supporting a stress-dependent model. (zemljicharpf2009vinculinandtalin pages 4-5, hershberger2021thecomplexand pages 3-4, hawley2020anassessmentof pages 12-15)

Protective factors

No validated protective VCL allele, modifier gene, diet, drug, or exposure has been identified. Avoidance of cardiotoxic exposures and early treatment are prudent risk reduction, not demonstrated primary prevention of DCM1W.

3. Phenotypes

Among 32 VCL-pLOF probands, 22 (68.8%) had onset before age 20, 16 (50%) by age 10, and 13 (40.6%) in infancy. Within the DCM subgroup, 17/19 (89.5%) had pediatric onset and mean onset/testing age was 4.3±6.4 years. Severity ranges from subclinical or absent disease in carriers to transplant-requiring heart failure. (hawley2020anassessmentof pages 8-12)

Quality of life: no DCM1W-specific EQ-5D, SF-36, PROMIS, or pediatric quality-of-life study was found. By clinical inference, symptomatic heart failure impairs feeding and growth in infants and exercise tolerance, schooling/work, and daily function in older patients; arrhythmia and device/transplant risk add psychosocial burden. These are DCM-general effects, not quantified VCL-specific outcomes.

4. Genetic and molecular information

Gene annotation

• Gene: VCL, vinculin.
• HGNC: HGNC:12665.
• Ensembl: ENSG00000035403. (OpenTargets Search: dilated cardiomyopathy-VCL)
• Location: chromosome 10q22.2; early literature reported the broader 10q22.1–q23 interval. (liu2022establishmentofa pages 1-2, olson2002metavinculinmutationsalter pages 1-2)
• Protein: vinculin, approximately 117 kDa and 1,066 aa; metavinculin is the muscle-specific isoform.
• Origin: reported disease-associated variants are germline, not somatic.

Variant spectrum and interpretation

• p.Leu954del: in-frame deletion affecting metavinculin; abnormal actin cross-linking in vitro.
• p.Arg975Trp: missense variant affecting metavinculin; abnormal cross-linking and grossly abnormal intercalated discs in one patient.
• p.Lys815Arg: missense; plausible but unproved, with possible MYBPC3 modification.
• c.625A>T (p.Met209Leu): heterozygous variant used to derive an iPSC line; the resource paper does not by itself establish pathogenicity.
• p.Arg547*: reported in infantile DCM with ventricular tachycardia.
• Recurrent p.Arg188* and p.Arg570***: rare pLOF observations in the aggregated study.
• Other classes: canonical splice-site, nonsense, frameshift, and multi-exon duplication variants. (hawley2020anassessmentof pages 4-8, hawley2020anassessmentof pages 18-20, wells2011familialdilatedcardiomyopathy pages 3-4, liu2022establishmentofa pages 1-2, olson2002metavinculinmutationsalter pages 1-2)

The estimated gnomAD pLOF prevalence was approximately 0.0003–0.00046 depending on quality and nonsense-mediated-decay filters. Twenty-three variants had MAF <0.00002. Thirteen of 14 recently assessed pLOF variants were classified by laboratories as VUS, reflecting limited segregation and individual-variant data. A pLOF consequence is therefore not sufficient by itself to label a variant pathogenic. (hawley2020anassessmentof pages 4-8, hawley2020anassessmentof pages 18-20, hawley2020anassessmentof pages 12-15)

Functional consequence

For metavinculin-tail variants, altered F-actin cross-linking is experimentally demonstrated and may represent abnormal/qualitatively altered function. For early truncating variants expected to undergo nonsense-mediated decay, haploinsufficiency is the leading model. Dominant-negative effects remain possible for selected stable mutant proteins but are not established across VCL variants.

Modifiers, epigenetics, and structural variation

Possible modifier genes are listed above, but none is validated for clinical prediction. No DCM1W-specific DNA-methylation, histone, chromatin, single-cell, spatial-transcriptomic, proteomic, metabolomic, or lipidomic signature has been replicated. Apart from a reported multi-exon duplication, no recurrent pathogenic chromosomal rearrangement is established. Routine karyotyping is not indicated for isolated DCM1W.

5. Environmental information

VCL-associated disease is genetic susceptibility expressed in a mechanically active organ. Relevant potentially avoidable stressors include heavy alcohol intake, cocaine/amphetamine exposure, cardiotoxic chemotherapy, uncontrolled hypertension, and unreviewed high-intensity exercise in individuals with active myocarditis, severe dysfunction, or ventricular arrhythmia. Viral infection and myocarditis may trigger decompensation but are not causes of the inherited VCL variant. (hershberger2021thecomplexand pages 3-4, hawley2020anassessmentof pages 12-15)

A mechanistically relevant infection observation comes from experimental/observational Chagas cardiomyopathy: Trypanosoma cruzi infection reduced or displaced vinculin from costameres, accompanied by irregular intercalated discs and reduced cadherin/β-catenin. This supports convergence on the same adhesion machinery but does not establish T. cruzi as a DCM1W trigger. (zemljicharpf2009vinculinandtalin pages 4-5, zemljicharpf2007cardiacmyocytespecificexcisionof pages 1-2)

Smoking, poor diet, obesity, diabetes, and inactivity worsen general cardiovascular and heart-failure risk, but no VCL-specific effect size exists.

6. Mechanism and pathophysiology

Ordered causal chain

1. A functionally damaging VCL/metavinculin variant leads to reduced protein dosage or altered vinculin–F-actin interaction.
2. Impaired vinculin function leads to weakened coupling of F-actin to cadherin-based intercalated-disc adhesions and integrin/talin-based costameres.
3. Weak cell–cell and cell–matrix anchorage results in abnormal adherens junctions, defective myofibril anchorage, intercalated-disc dissolution, and inefficient force transmission.
4. Junctional remodeling leads to reduced cadherin and β1-integrin and lateral redistribution of connexin-43; in mice this results in slowed/abnormal conduction and ventricular tachycardia.
5. Repeated contraction and mechanical loading are inferred to cause cardiomyocyte mechanical injury and maladaptive mechanotransduction; pressure overload magnifies this branch.
6. Mechanical branch: impaired force transfer and myocyte dysfunction lead to reduced contractility, compensatory chamber enlargement, and adverse remodeling.
7. Electrical branch: connexin/junction disorganization leads to conduction heterogeneity, ventricular arrhythmia, and possible sudden death.
8. Downstream myocyte injury is inferred to promote neurohormonal activation, fibrosis, energetic stress, and secondary valve regurgitation.
9. These processes result in LV or biventricular dilation, reduced ejection fraction, symptomatic heart failure, and—in severe cases—LVAD or transplantation.

Evidence and biological detail

The first three steps are supported by human biochemical and ultrastructural evidence: p.Leu954del and p.Arg975Trp significantly altered actin cross-linking, and the p.Arg975Trp carrier had grossly abnormal intercalated discs. (olson2002metavinculinmutationsalter pages 1-2)

Cardiac-specific Vcl knockout provides direct in-vivo evidence for the junctional/electrical branch. Before overt dysfunction, knockout hearts showed adherens-junction abnormalities, intercalated-disc dissolution, reduced cadherin and β1D-integrin, and connexin-43 mislocalization. Forty-nine percent of knockout mice died suddenly before 3 months, with telemetry documenting ventricular tachycardia; survivors developed DCM and died before 6 months. The authors concluded that Vcl is required for preservation of normal cell–cell and cell–matrix adhesive structures. DOI/URL: https://doi.org/10.1128/MCB.00728-07; published online 4 September 2007. (zemljicharpf2007cardiacmyocytespecificexcisionof pages 1-2)

Heterozygous mice had widened QRS complexes and abnormal junctional architecture despite relatively preserved basal function; pressure overload produced marked mortality and progressive LV dysfunction. Cardiac knockout also caused disorganized mitochondria before overt failure, although a primary VCL-specific metabolic defect has not been demonstrated in humans. (zemljicharpf2009vinculinandtalin pages 4-5)

A recent post-translational study found that VCL Y822 phosphorylation peaks during developmental adhesion remodeling, rises after adult cardiac injury, and regulates both cell–matrix and cell–cell adhesion. Homozygous Y822F mice developed cardiac dysfunction at 28 weeks, and cultured mutant cardiomyocytes had defective cell–cell adhesion organization. This refines the mechanism toward dynamically regulated mechanotransduction, but Y822F is a model allele rather than an established DCM1W patient variant. DOI/URL: https://doi.org/10.1242/jcs.263984; accepted/published across late 2024–2025. (li2024vinculiny822phosphorylation pages 1-3)

Relevant pathways: focal adhesion/integrin–talin–vinculin–actin coupling; cadherin–catenin adherens junctions; connexin-43 gap-junction organization; FAK/Src and downstream PI3K–AKT/Wnt mechanotransduction are biologically relevant, but no specific PI3K, MAPK, mTOR, or Wnt abnormality has been established in human DCM1W.

Suggested GO biological processes: GO:0007155 cell adhesion; GO:0051017 actin-filament bundle assembly; GO:0007015 actin-filament organization; GO:0006936 muscle contraction; GO:0003015 heart process; GO:0007507 heart development; GO:0055001 muscle-cell development; GO:0072659 protein localization to plasma membrane.

Suggested cell types: CL:0000746 cardiac muscle cell/cardiomyocyte; ventricular cardiomyocyte where a current CL child term is available; secondary cardiac fibroblasts and endothelial cells are plausible remodeling participants but not demonstrated primary VCL targets.

7. Anatomical structures affected

• Primary organ: heart, especially left-ventricular myocardium; biventricular disease may occur.
• Primary tissue/cell: cardiac muscle tissue and cardiomyocytes.
• Substructures: intercalated discs, adherens junctions, gap-junction organization, costameres/focal adhesions, sarcolemma, actin cytoskeleton, and myofibril anchorage sites.
• Secondary organs: lungs, liver, kidneys, and systemic circulation can be affected through congestion or low output, not primary VCL lesions.
• Lateralization: not applicable; disease is not unilateral.

Suggested UBERON: UBERON:0000948 heart; UBERON:0002084 heart left ventricle; UBERON:0002080 heart right ventricle; UBERON:0002349 myocardium. GO cellular component: GO:0005925 focal adhesion; GO:0005912 adherens junction; GO:0005921 gap junction; GO:0005886 plasma membrane; GO:0030018 Z disc; GO:0005739 mitochondrion. (zemljicharpf2007cardiacmyocytespecificexcisionof pages 1-2, olson2002metavinculinmutationsalter pages 1-2)

8. Temporal development

Onset is highly variable, but pLOF cohorts are strongly enriched for pediatric and infantile presentation. Early disease may be insidious in genotype-positive relatives or acute in an infant presenting with severe heart failure. Progression can follow several trajectories: stable subclinical disease; progressive dilation and failure; arrhythmia before severe pump dysfunction; or reverse remodeling with improved/recovered EF. (hawley2020anassessmentof pages 8-12, zahavich2023heartfailurewith pages 1-2)

In the six-infant series, ventricular recovery occurred 0.3–3.2 years after diagnosis, at a median age of 2.7 years. The abstract’s key statement was: “Five patients (83%) showed normalization of LV function”; one patient progressed to transplant. Published online 7 August 2023; DOI/URL: https://doi.org/10.1007/s12265-023-10421-6. (zahavich2023heartfailurewith pages 1-2)

Recovery should be termed remission or HF with improved/recovered EF, not cure. Contemporary guidance stresses that improved EF may not represent resolution of the cardiomyopathic process and supports continued therapy to reduce relapse. (badger2023summaryandcomparison pages 6-7)

Critical intervention windows include presymptomatic family detection, the first presentation with ventricular dysfunction, and the initial months of guideline-directed therapy when reverse remodeling may occur.

9. Inheritance and population characteristics

Inheritance

The historical designation implies autosomal-dominant inheritance, and affected individuals are generally heterozygous. However, modern family data indicate incomplete, probably age- and stress-dependent penetrance, variable expressivity, and possible oligogenic modification. No robust evidence supports anticipation. Germline mosaicism is theoretically possible for any de novo variant but has not been documented as a recurrent DCM1W feature. No established founder variant, consanguinity effect, or population-specific carrier frequency exists. (hawley2020anassessmentof pages 12-15, hawley2020anassessmentof pages 8-12)

Epidemiology

No reliable prevalence or incidence exists for DCM1W itself. In the large pLOF study, rare VCL pLOF alleles occurred in approximately 0.03–0.046% of gnomAD participants, but this is not disease prevalence because penetrance is low and variant interpretation differs. (hawley2020anassessmentof pages 4-8, hawley2020anassessmentof pages 18-20)

For DCM generally, recorded disease is more common in males; one population EHR study found DCM approximately twice as common in men, but this cannot be assigned to VCL specifically. No VCL-specific sex ratio, geographic clustering, or ethnic enrichment is established. The available iPSC donor was a 65-year-old Han Chinese man, which is a single resource case rather than population evidence. (liu2022establishmentofa pages 1-2)

Family history is insensitive: a 2024 review reports that only 11% of one idiopathic-DCM cohort reported family history, whereas echocardiographic screening identified familial disease in 32%. Across DCM, approximately 30% meets conventional familial definitions, increasing above 50% when subclinical LV abnormalities are counted. (newman2024dilatedcardiomyopathya pages 2-4)

10. Diagnostics

Clinical evaluation

1. Obtain symptoms, examination, medication/toxin/infection history, and a three-generation pedigree.
2. Perform ECG and ambulatory monitoring for conduction disease and atrial/ventricular arrhythmia.
3. Use echocardiography to quantify chamber dimensions, LVEF, strain, RV function, and functional valve regurgitation.
4. Use CMR for accurate biventricular volumes and late gadolinium enhancement. Mid-wall LGE can accompany genetic DCM or myocarditis; subepicardial patterns suggest myocarditis, sarcoidosis, or chemotherapy injury.
5. Laboratory evaluation may include BNP/NT-proBNP, troponin, CBC, electrolytes, renal/liver/thyroid studies, iron indices, and phenotype-directed metabolic/infectious tests.
6. Exclude ischemic heart disease and sufficient hypertension, valve disease, congenital disease, sustained tachyarrhythmia, toxin exposure, endocrine/metabolic disease, and active myocarditis.
7. Reserve endomyocardial biopsy for selected suspected myocarditis, infiltrative/inflammatory disease, or rapidly progressive unexplained presentations; myocarditis confirmation requires histology/immunohistochemistry and, where appropriate, pathogen nucleic-acid testing. (sammani2021diagnosisandrisk pages 2-4, grasso2024thenew2023 pages 1-2)

Genetic testing

A curated cardiomyopathy NGS panel that includes VCL and robust DCM genes is the practical first test. It should include copy-number analysis. WES or WGS is useful when panel testing is negative, the phenotype is syndromic, or structural/noncoding variants are suspected. RNA sequencing from an informative tissue or validated cellular system can resolve selected splice variants, but it is not routine. CMA is appropriate for congenital anomalies/developmental disability; karyotype/FISH, mitochondrial-genome, and repeat-expansion tests are phenotype-driven rather than routine DCM1W tests. (sammani2021diagnosisandrisk pages 2-4, newman2024dilatedcardiomyopathya pages 2-4)

Interpret variants under ACMG/AMP criteria with gene- and disease-specific evidence. Confirm a pathogenic/likely pathogenic result orthogonally where required and perform segregation. Do not use a VUS for predictive cascade testing or irreversible management. This is especially important for VCL because 13/14 recently assessed pLOF alleles were VUS. (hawley2020anassessmentof pages 4-8, hawley2020anassessmentof pages 12-15)

Screening

First-degree relatives should receive clinical screening with history, ECG, and echocardiography; CMR/Holter are added according to age and findings. When a familial pathogenic/likely pathogenic variant is established, offer cascade testing and lifelong surveillance to genotype-positive relatives. Up to 20% of apparently asymptomatic relatives across DCM cohorts have overt DCM at initial assessment. (newman2024dilatedcardiomyopathya pages 2-4)

Differential diagnosis

Exclude ischemic cardiomyopathy; myocarditis; tachycardia-induced, peripartum, alcohol- or chemotherapy-associated cardiomyopathy; endocrine/metabolic disease; neuromuscular/mitochondrial disorders; valve or congenital disease; arrhythmogenic cardiomyopathy; LV noncompaction trait; and other genetic DCMs such as TTN-, LMNA-, FLNC-, DSP-, BAG3-, RBM20-, and sarcomeric-gene disease.

Implementation gap: among 101,919 newly diagnosed US DCM patients in 2017–2021 EHR/claims data, only 827 (0.8%) had evidence of genetic testing within six months. Published 17 October 2023; DOI/URL: https://doi.org/10.3389/fcvm.2023.1272433. (longoni2023realworldutilizationof pages 1-2)

11. Outcome and prognosis

DCM1W-specific survival curves are unavailable. Prognosis is heterogeneous because VCL alleles are incompletely penetrant and reported cohorts mix variant mechanisms. Favorable reverse remodeling is possible, particularly in the small infant series, but arrhythmia, sudden death, end-stage failure, LVAD, and transplantation remain possible. (zahavich2023heartfailurewith pages 1-2, zemljicharpf2007cardiacmyocytespecificexcisionof pages 1-2)

For context—not DCM1W-specific—a 1,284-patient nonischemic DCM registry observed major contemporary improvement. In the 2005–2015 enrollment period, annual rates were 1.46 events/100 patient-years for all-cause death/transplant/VAD, 0.82 for cardiovascular death/transplant/VAD, and 0.15 for sudden cardiac death. Published June 2020; DOI/URL: https://doi.org/10.1002/ejhf.1914. (merlo2020contemporarysurvivaltrends pages 1-4)

Prognostic factors should include baseline and serial LVEF/volumes, RV dysfunction, NYHA class, ventricular arrhythmia, conduction disease, syncope, fibrosis/LGE, biomarker burden, response to therapy, and family history. No VCL-specific circulating or molecular prognostic biomarker is validated. The 83% infant recovery estimate must not be generalized beyond that six-patient series.

12. Treatment

Standard treatment

No approved VCL-directed therapy exists. Treat the phenotype according to contemporary HFrEF/DCM guidance:

• ARNI, or ACE inhibitor/ARB where ARNI is unsuitable;
• evidence-based β-blocker;
• mineralocorticoid-receptor antagonist;
• SGLT2 inhibitor;
• loop diuretic for congestion;
• additional therapy for iron deficiency, atrial fibrillation, thromboembolism, or selected persistent symptoms as indicated.

The six VCL-positive infants received an ACE inhibitor and β-blocker. Five recovered ventricular function, but causality cannot be inferred from an uncontrolled series. (zahavich2023heartfailurewith pages 1-2)

Suggested NCIT intervention concepts: Angiotensin-Converting Enzyme Inhibitor; Angiotensin Receptor–Neprilysin Inhibitor; Beta-Adrenergic Blocker; Mineralocorticoid Receptor Antagonist; Sodium-Glucose Cotransporter 2 Inhibitor; Diuretic Therapy.

Devices and advanced care

Consider ICD for standard primary/secondary-prevention indications after adequate therapy and individualized arrhythmic-risk assessment. Unlike LMNA, FLNC, DSP, or selected RBM20 disease, current evidence does not justify an ICD solely because of a VCL variant. CRT is used for appropriate electrical dyssynchrony and persistent systolic dysfunction. Advanced refractory disease may require LVAD or transplantation. Suggested NCIT concepts include Implantable Cardioverter Defibrillator, Cardiac Resynchronization Therapy, Ventricular Assist Device, and Heart Transplantation. (badger2023summaryandcomparison pages 6-7, merlo2020contemporarysurvivaltrends pages 1-4)

Continue guideline-directed therapy after EF improvement because recovered EF does not necessarily mean elimination of the underlying substrate. Exercise prescription should be individualized by ventricular function, rhythm burden, and symptoms; cardiac rehabilitation is appropriate for stable patients. (badger2023summaryandcomparison pages 6-7)

Experimental therapeutics

No VCL-specific gene replacement, editing, ASO, siRNA, mRNA, cell therapy, or targeted drug trial was identified. DCM trials involving cell therapy or gene therapy for other genotypes cannot be treated as DCM1W evidence. Current VCL research is preclinical and focuses on adhesion/mechanotransduction and disease modeling.

13. Prevention

Primary prevention: the inherited allele cannot presently be prevented after conception. Risk reduction consists of avoiding heavy alcohol and illicit stimulants, controlling blood pressure and metabolic risk, reviewing cardiotoxic therapy, and promptly evaluating myocarditis-like illness. These measures are biologically prudent but untested specifically in VCL carriers.

Secondary prevention: genetic counseling, cascade testing for an established pathogenic/likely pathogenic familial variant, and serial ECG/imaging permit presymptomatic detection. There is no population or newborn screening program for DCM1W. Prenatal diagnosis and PGT-M are technically possible only when the familial variant is sufficiently established; reduced penetrance must be emphasized. A 2024 PGT guideline study developed a severity/penetrance model because inherited cardiac diseases vary greatly in predictiveness. DOI/URL: https://doi.org/10.1161/CIRCGEN.123.004416.

Tertiary prevention: sustained guideline-directed therapy, arrhythmia surveillance, vaccination according to standard schedules, sodium/fluid counseling when clinically indicated, rehabilitation, and timely ICD/CRT/advanced-HF referral reduce complications. No DCM1W-specific vaccine or prophylactic medication exists.

14. Other species and natural disease

• Human: Homo sapiens, NCBI Taxon 9606.
• Mouse ortholog/model: Mus musculus, Taxon 10090, gene Vcl.
• Zebrafish ortholog/model: Danio rerio, Taxon 7955, vinculin paralogs/orthologs.

No well-established, naturally occurring veterinary syndrome equivalent to human DCM1W was identified in dogs, cats, livestock, or wildlife. Consequently, no breed-specific VBO term is justified. The relevant animal evidence is experimentally induced genetic disease, not zoonosis. There is no transmission or cross-species infectious risk.

Vinculin’s strong evolutionary conservation and preservation of cardiac adhesion phenotypes support comparative validity. Zebrafish vinculin knockdown caused impaired contractility, pericardial edema, and blood congestion; cardiac-specific mouse deletion caused junctional failure, arrhythmia, DCM, and early death. (wells2011familialdilatedcardiomyopathy pages 3-4, zemljicharpf2007cardiacmyocytespecificexcisionof pages 1-2)

15. Model organisms and experimental systems

Mouse models

1. Cardiomyocyte-specific Vcl knockout: Cre-loxP model. It reproduces intercalated-disc dissolution, reduced cadherin/β1-integrin, connexin-43 mislocalization, conduction defects, ventricular tachycardia, sudden death, and later DCM. It is a severe null model and may overstate effects of heterozygous human alleles. (zemljicharpf2007cardiacmyocytespecificexcisionof pages 1-2)
2. Vcl heterozygous knockout: shows widened QRS and junctional abnormalities with strong pressure-overload vulnerability, modeling incomplete penetrance and gene–environment/mechanical-stress interaction. (zemljicharpf2009vinculinandtalin pages 4-5)
3. Vcl Y822F knock-in: models defective post-translational regulation; homozygotes show adhesion defects and dysfunction by 28 weeks. It illuminates mechanism but is not a validated patient genotype. (li2024vinculiny822phosphorylation pages 1-3)

Zebrafish

Morpholino/knockdown evidence shows impaired cardiac contraction, edema, and blood congestion. Advantages are rapid developmental and contractility assays; limitations include paralog biology, two-chamber anatomy, and developmental knockdown artifacts. (wells2011familialdilatedcardiomyopathy pages 3-4)

Human cellular model

The iPSC line ZZUNEUi026-A was generated from peripheral-blood mononuclear cells of a 65-year-old Han Chinese man with DCM and heterozygous VCL c.625A>T (p.Met209Leu). It has a normal 46,XY karyotype, expresses pluripotency markers, differentiates into all three germ layers, and can generate cardiomyocytes. It is a model resource rather than proof that p.Met209Leu is pathogenic; an isogenic corrected control and mature engineered-heart-tissue experiments would be needed for causal inference. Published online 10 May 2022; DOI/URL: https://doi.org/10.1016/j.scr.2022.102812. (liu2022establishmentofa pages 1-2)

No validated DCM1W organoid, large-animal model, CRISPR-screen result, or integrated single-cell/spatial multi-omics atlas was identified.

Overall expert interpretation

The most defensible current formulation is: VCL is a biologically compelling DCM gene, but its alleles do not constitute a uniform disease mechanism. Metavinculin-tail p.Arg975Trp and p.Leu954del have direct functional evidence for abnormal actin organization and force transmission. In contrast, VCL truncating alleles are enriched in predominantly pediatric DCM but frequently occur with unaffected carriers or additional genetic findings; they should often be treated as reduced-penetrance risk alleles unless variant-level segregation and functional data justify pathogenic classification. (hawley2020anassessmentof pages 12-15, hawley2020anassessmentof pages 8-12, olson2002metavinculinmutationsalter pages 1-2)

The important 2023 development is recognition of a severe-at-presentation yet often recoverable infantile phenotype: “over 80% of infant DCM cases with LOF VCL variants” recovered EF in the reported series. That observation is clinically useful for counseling but remains preliminary because five variants were VUS, four patients carried additional cardiomyopathy-gene VUS, and the cohort contained only six infants. (zahavich2023heartfailurewith pages 1-2)

For knowledge-base implementation, DCM1W should therefore be represented with explicit evidence granularity: variant, transcript/isoform, functional result, segregation, co-occurring variants, age, environmental stressors, and ACMG classification. A simple binary “VCL mutation causes DCM1W” assertion would overstate present evidence.

References

1. (hawley2020anassessmentof pages 12-15): Megan H. Hawley, Naif Almontashiri, Leslie G. Biesecker, Natalie Berger, Wendy K. Chung, John Garcia, Theresa A. Grebe, Melissa A. Kelly, Matthew S. Lebo, Daniela Macaya, Hui Mei, Julia Platt, Gabi Richard, Ashley Ryan, Kate L. Thomson, Matteo Vatta, Roddy Walsh, James S. Ware, Matthew Wheeler, Hana Zouk, Heather Mason‐Suares, and Birgit Funke. An assessment of the role of vinculin loss of function variants in inherited cardiomyopathy. Jun 2020. URL: https://doi.org/10.1002/humu.24061, doi:10.1002/humu.24061. This article has 19 citations and is from a domain leading peer-reviewed journal.

2. (hawley2020anassessmentof pages 8-12): Megan H. Hawley, Naif Almontashiri, Leslie G. Biesecker, Natalie Berger, Wendy K. Chung, John Garcia, Theresa A. Grebe, Melissa A. Kelly, Matthew S. Lebo, Daniela Macaya, Hui Mei, Julia Platt, Gabi Richard, Ashley Ryan, Kate L. Thomson, Matteo Vatta, Roddy Walsh, James S. Ware, Matthew Wheeler, Hana Zouk, Heather Mason‐Suares, and Birgit Funke. An assessment of the role of vinculin loss of function variants in inherited cardiomyopathy. Jun 2020. URL: https://doi.org/10.1002/humu.24061, doi:10.1002/humu.24061. This article has 19 citations and is from a domain leading peer-reviewed journal.

3. (olson2002metavinculinmutationsalter pages 1-2): Timothy M. Olson, Susanne Illenberger, Nina Y. Kishimoto, Stefan Huttelmaier, Mark T. Keating, and Brigitte M. Jockusch. Metavinculin mutations alter actin interaction in dilated cardiomyopathy. Circulation: Journal of the American Heart Association, 105:431-437, Jan 2002. URL: https://doi.org/10.1161/hc0402.102930, doi:10.1161/hc0402.102930. This article has 400 citations.

4. (zahavich2023heartfailurewith pages 1-2): Laura Zahavich, Rajadurai Akilen, Kristen George, and Seema Mital. Heart failure with recovered ejection fraction in patients with vinculin loss-of-function variants. Journal of Cardiovascular Translational Research, 16:1303-1309, Aug 2023. URL: https://doi.org/10.1007/s12265-023-10421-6, doi:10.1007/s12265-023-10421-6. This article has 5 citations and is from a peer-reviewed journal.

5. (OpenTargets Search: dilated cardiomyopathy-VCL): Open Targets Query (dilated cardiomyopathy-VCL, 7 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

6. (zemljicharpf2007cardiacmyocytespecificexcisionof pages 1-2): Alice E. Zemljic-Harpf, Joel C. Miller, Scott A. Henderson, Adam T. Wright, Ana Maria Manso, Laila Elsherif, Nancy D. Dalton, Andrea K. Thor, Guy A. Perkins, Andrew D. McCulloch, and Robert S. Ross. Cardiac-myocyte-specific excision of the vinculin gene disrupts cellular junctions, causing sudden death or dilated cardiomyopathy. Nov 2007. URL: https://doi.org/10.1128/mcb.00728-07, doi:10.1128/mcb.00728-07. This article has 244 citations and is from a domain leading peer-reviewed journal.

7. (li2024vinculiny822phosphorylation pages 1-3): Xiaofei Li, Rainy Wortelboer, Yi Song, Sahana Balasubramanian, Callie McLain, Alex Hernandez Manriquez, Joseph D. Suh, Brenton D. Hoffman, Adam V. Kwiatkowski, and Glenn L. Radice. Vinculin y822 phosphorylation regulates adhesion remodeling during cardiomyocyte maturation. Journal of Cell Science, Dec 2024. URL: https://doi.org/10.1242/jcs.263984, doi:10.1242/jcs.263984. This article has 1 citations and is from a domain leading peer-reviewed journal.

8. (hawley2020anassessmentof pages 4-8): Megan H. Hawley, Naif Almontashiri, Leslie G. Biesecker, Natalie Berger, Wendy K. Chung, John Garcia, Theresa A. Grebe, Melissa A. Kelly, Matthew S. Lebo, Daniela Macaya, Hui Mei, Julia Platt, Gabi Richard, Ashley Ryan, Kate L. Thomson, Matteo Vatta, Roddy Walsh, James S. Ware, Matthew Wheeler, Hana Zouk, Heather Mason‐Suares, and Birgit Funke. An assessment of the role of vinculin loss of function variants in inherited cardiomyopathy. Jun 2020. URL: https://doi.org/10.1002/humu.24061, doi:10.1002/humu.24061. This article has 19 citations and is from a domain leading peer-reviewed journal.

9. (hawley2020anassessmentof pages 18-20): Megan H. Hawley, Naif Almontashiri, Leslie G. Biesecker, Natalie Berger, Wendy K. Chung, John Garcia, Theresa A. Grebe, Melissa A. Kelly, Matthew S. Lebo, Daniela Macaya, Hui Mei, Julia Platt, Gabi Richard, Ashley Ryan, Kate L. Thomson, Matteo Vatta, Roddy Walsh, James S. Ware, Matthew Wheeler, Hana Zouk, Heather Mason‐Suares, and Birgit Funke. An assessment of the role of vinculin loss of function variants in inherited cardiomyopathy. Jun 2020. URL: https://doi.org/10.1002/humu.24061, doi:10.1002/humu.24061. This article has 19 citations and is from a domain leading peer-reviewed journal.

10. (wells2011familialdilatedcardiomyopathy pages 3-4): Quinn S. Wells, Natalie L. Ausborn, Birgit H. Funke, Jean P. Pfotenhauer, Joseph L. Fredi, Samantha Baxter, Thomas G. DiSalvo, and Charles C. Hong. Familial dilated cardiomyopathy associated with congenital defects in the setting of a novel vcl mutation (lys815arg) in conjunction with a known mypbc3 variant. Cardiogenetics, 1 1:e10, Aug 2011. URL: https://doi.org/10.4081/cardiogenetics.2011.e10, doi:10.4081/cardiogenetics.2011.e10. This article has 21 citations.

11. (zemljicharpf2009vinculinandtalin pages 4-5): Alice Zemljic-Harpf, Ana Maria Manso, and Robert S. Ross. Vinculin and talin. Journal of Investigative Medicine, 57:849-855, Dec 2009. URL: https://doi.org/10.2310/jim.0b013e3181c5e074, doi:10.2310/jim.0b013e3181c5e074. This article has 84 citations and is from a peer-reviewed journal.

12. (sammani2021diagnosisandrisk pages 2-4): Arjan Sammani, Annette F. Baas, Folkert W. Asselbergs, and Anneline S. J. M. te Riele. Diagnosis and risk prediction of dilated cardiomyopathy in the era of big data and genomics. Journal of Clinical Medicine, 10:921, Feb 2021. URL: https://doi.org/10.3390/jcm10050921, doi:10.3390/jcm10050921. This article has 45 citations.

13. (newman2024dilatedcardiomyopathya pages 2-4): Noah A. Newman and Michael A. Burke. Dilated cardiomyopathy: a genetic journey from past to future. International Journal of Molecular Sciences, 25:11460, Oct 2024. URL: https://doi.org/10.3390/ijms252111460, doi:10.3390/ijms252111460. This article has 28 citations.

14. (grasso2024thenew2023 pages 1-2): Maurizia Grasso, Davide Bondavalli, Viviana Vilardo, Claudia Cavaliere, Ilaria Gatti, Alessandro Di Toro, Lorenzo Giuliani, Mario Urtis, Michela Ferrari, Barbara Cattadori, Alessandra Serio, Carlo Pellegrini, and Eloisa Arbustini. The new 2023 esc guidelines for the management of cardiomyopathies: a guiding path for cardiologist decisions. European Heart Journal Supplements : Journal of the European Society of Cardiology, 26:i1-i5, Apr 2024. URL: https://doi.org/10.1093/eurheartjsupp/suae002, doi:10.1093/eurheartjsupp/suae002. This article has 18 citations.

15. (longoni2023realworldutilizationof pages 1-2): Mauro Longoni, Kanchan Bhasin, Andrew Ward, Donghyun Lee, McKenna Nisson, Sucheta Bhatt, Fatima Rodriguez, and Rajesh Dash. Real-world utilization of guideline-directed genetic testing in inherited cardiovascular diseases. Frontiers in Cardiovascular Medicine, Oct 2023. URL: https://doi.org/10.3389/fcvm.2023.1272433, doi:10.3389/fcvm.2023.1272433. This article has 32 citations and is from a peer-reviewed journal.

16. (badger2023summaryandcomparison pages 6-7): Sarah Badger, James McVeigh, and Praveen Indraratna. Summary and comparison of the 2022 acc/aha/hfsa and 2021 esc heart failure guidelines. Cardiology and Therapy, 12:571-588, Aug 2023. URL: https://doi.org/10.1007/s40119-023-00328-3, doi:10.1007/s40119-023-00328-3. This article has 12 citations and is from a peer-reviewed journal.

17. (liu2022establishmentofa pages 1-2): Yangyang Liu, Xiao-Wei Li, Xiaoyan Zhao, Jianzeng Dong, Chunyang Zhang, and Tao Lin. Establishment of a human ipsc (zzuneui026-a) from a dilated cardiomyopathy patient carrying heterozygous vinculin (c. 625a > t) mutant. Jul 2022. URL: https://doi.org/10.1016/j.scr.2022.102812, doi:10.1016/j.scr.2022.102812. This article has 2 citations and is from a peer-reviewed journal.

18. (hawley2020anassessmentof pages 15-18): Megan H. Hawley, Naif Almontashiri, Leslie G. Biesecker, Natalie Berger, Wendy K. Chung, John Garcia, Theresa A. Grebe, Melissa A. Kelly, Matthew S. Lebo, Daniela Macaya, Hui Mei, Julia Platt, Gabi Richard, Ashley Ryan, Kate L. Thomson, Matteo Vatta, Roddy Walsh, James S. Ware, Matthew Wheeler, Hana Zouk, Heather Mason‐Suares, and Birgit Funke. An assessment of the role of vinculin loss of function variants in inherited cardiomyopathy. Jun 2020. URL: https://doi.org/10.1002/humu.24061, doi:10.1002/humu.24061. This article has 19 citations and is from a domain leading peer-reviewed journal.

19. (merlo2020contemporarysurvivaltrends pages 1-4): Marco Merlo, Antonio Cannatà, Carola Pio Loco, Davide Stolfo, Giulia Barbati, Jessica Artico, Piero Gentile, Valerio De Paris, Federica Ramani, Massimo Zecchin, Marta Gigli, Bruno Pinamonti, Renata Korcova, Andrea Di Lenarda, Mauro Giacca, Luisa Mestroni, Paolo G. Camici, and Gianfranco Sinagra. Contemporary survival trends and aetiological characterization in non-ischaemic dilated cardiomyopathy. Jun 2020. URL: https://doi.org/10.1002/ejhf.1914, doi:10.1002/ejhf.1914. This article has 101 citations and is from a highest quality peer-reviewed journal.

20. (hershberger2021thecomplexand pages 3-4): Ray E. Hershberger, Jason Cowan, Elizabeth Jordan, and Daniel D. Kinnamon. The complex and diverse genetic architecture of dilated cardiomyopathy. Circulation research, 128 10:1514-1532, May 2021. URL: https://doi.org/10.1161/circresaha.121.318157, doi:10.1161/circresaha.121.318157. This article has 106 citations and is from a highest quality peer-reviewed journal.

Artifacts

• Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• HP:0001644 (4 mentions) - the report calls it "19/32 (59.4%) VCL-pLOF probands"; HP calls it Dilated cardiomyopathy
• HP:0001635 (2 mentions) - the report calls it "Presenting syndrome in the infant series; exact broader frequency unavailable"; HP calls it Congestive heart failure
• HP:0001711 (2 mentions) - the report calls it "Median LVEF 24% in six infants"; HP calls it Abnormal left ventricle morphology
• HP:0030682 (1 mention) - the report calls it "2/32 pLOF probands"; HP calls it Left ventricular noncompaction
• HP:0001653 (1 mention) - the report calls it "DCM-general; subtype frequency unavailable"; HP calls it Mitral regurgitation

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA.